| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | KU-55933 | CTRPv2 | pan-cancer | AAC | -0.0038 | 0.9 |
| mRNA | BRD-K30019337 | CTRPv2 | pan-cancer | AAC | 0.007 | 0.9 |
| mRNA | N9-isopropylolomoucine | CTRPv2 | pan-cancer | AAC | 0.0036 | 0.9 |
| mRNA | TGX221 | CTRPv2 | pan-cancer | AAC | -0.0036 | 0.9 |
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.0037 | 0.9 |
| mRNA | BRD-K61166597 | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |
| mRNA | BRD-K27224038 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | AZD-7545 | CTRPv2 | pan-cancer | AAC | 0.0029 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0026 | 0.9 |